SlideShare una empresa de Scribd logo
1 de 63
By

MedDRA
Basics
Somnath Mondal

Technical Associate (PVPI)
Dept. of Clinical & Experimental
Pharmacology
School of tropical Medicine,
Kolkata
Dated 20th Nov continuance from 7th Nov,2013
Agenda
1. Introduction to MedDRA
2. ABC of Coding
3. Brief History of MedDRA

Development

4. Scope of MedDRA
5. MedDRA Term

vs.

MedDRA Code

6. Basic of Structural Elements of the
Terminology
What is MedDRA?
Med =

Medical

D =

Dictionary

R = Regulatory
A = Activities
MedDRA Definition
MedDRA

is

a

clinically-validated

international medical terminology

used by regulatory authorities and the
regulated biopharmaceutical industry.

The terminology is used through the
entire regulatory process, from
pre-marketing to post-marketing,
and for data entry, retrieval,
evaluation, and presentation.
Requirements for MedDRA development
• International applicability
• Supported and used by both industry and regulators
• Broader coverage of health data
• Increased specificity
• Structure to support analysis and presentation
• Centrally and externally maintained
• Compatible with IT systems and tools
Rationale For MedDRA
Global Standardization and Universal Harmonization
Across Regulatory Agencies
Across Multinational Pharmaceutical Companies
Necessary through out Product Life Cycle
Necessary for Electronic Data Transfer

Avoid Translation Distortions and Errors Across Countries
Save Time:

No need to cross reference through life time of
product.
No need to Translate

Provide a classification for a wide range of clinical
information, able to support for multiple medical product
areas
Who participates in the MedDRA ?

Representatives of Authorities and Pharmaceutical Companies from :

Europe

Japan

United States

European Union

All reports (electronic) – January 2003
 EudraCT
SUSARs
 Starting 2003

all severe single case safety reports
going back to 1995 must be electronically submitted
before the start of 2004.

 Internal adverse event database
Japanese Ministry of Health, Labour and Welfare

 Required use of MedDRA for electronic
filing start 1 October 2003

 Proposed Rule for Safety Reporting
Requirements (2003): FDA proposes to use
MedDRA for post marketing safety reports

MedDRA to be used in Periodic Infection &
Safety Reports from April 2004

Observers:

WHO, European Free Trade Association (EFTA), Nordic Countries (Denmark,
Finland, Iceland, Norway and Sweden, Greenland), Canada, Australia
Sample of Current Regulators
MedDRA
ABC of Coding
Why Do Medical and Drug Terms Need to Be
Classified?

Investigators report the same medical and treatment terms (called
verbatim terms) in many different ways on the CRF/ ADR Reporting
Form.
In order to compare the frequency of adverse events in drug
treatment versus non treatment groups the terms need to be classified
into standardized terminology.
Why?
• To facilitate the aggregation of verbatim
reports into medically meaningful groupings
so that they can be reviewed, analysed and
communicated to the regulatory authorities.
• To ensure the accurate, unbiased &
consistent classification of CRF verbatim
terms as reported by the investigators
What is Coding?
Etymology: L, caudex, book
The process of organizing information into
categories, which are assigned codes for the
purposes of sorting, storing, and retrieving the data.
The process of transforming qualitative data into
numerical data that can be entered into a computer
file.
Medical coding is essentially the process of assigning
formal, standardized medical codes to patient
medical records.
Why is Medical Coding?
Medical coding is the transformation of narrative
descriptions of diseases, injuries, and healthcare procedures
into numeric or alphanumeric designations (that is, code
numbers).

The code numbers are detailed in order to
Accurately describe the diagnoses (that is, what is wrong with the patient).
and
The procedures performed to test or correct these diagnoses.

Because medicine is not always an exact science,
codes were developed to identify all reasons for
seeking healthcare.
Why do Medical Coding?
If we search for "medical coding" on web , we will be driven to websites which deals
with the ICD (9,10 etc.), CPT (Current Procedural Terminology) or HCPCS
( Healthcare Common Procedure Coding System) medical coding particularly deals
with mapping various medical diagnosis and procedures to codes.

Common uses of medical codes in healthcare include:
Identifying symptoms that must be evaluated and to alert other
healthcare professionals to life-threatening allergies.

The services performed for reimbursement
ReportingICD or CPT coding is out of scope here in this
presentation.
Helping with administrative functions such as staffing, scheduling, and
adding or decreasing healthcare services
Comparing facilities and planning for new services in underserved areas
These mostly deals with medical insurance data and medical billing which is different from
the coding in all phases of drug development.
Coding decisions during all phases of drug development
directly impact

submissions for New Drug Applications (NDAs),
safety surveillance
and
product labelling.
The success of a submission to the concerned regulatory

authority (e.g. USFDA, EMEA or DCGI?) can be significantly
impacted by the analysis of adverse events, medical history
and concomitant medications. The analysis relies on the
interpretation of what has been transcribed from the subject
CRF (Case Report Form) or ADR reporting form.
Ultimately, medical coding data permits access to health records according
The coding of patient data is critical in the grouping, analysis, and
to diagnoses and procedures for use in clinical care, research, education
reporting of data.
and for regulatory activities.
Brief History of MedDRA
Development
Pre-MedDRA Era
The essentiality and importance for an internationally accepted medical
terminology, classification system was recognized at the First
International Statistical Conference in Brussels in 1853 to evaluate

medical data statistically to optimize and regulate public
health issues globally.

The standardization effort bore fruit in 1969 with the FDA’s
use of the COSTART (Coding Symbols for a Thesaurus of
Adverse Reaction Terms) dictionary.
For the next quarter century, adverse event coding was
dominated
by
WHOART
(WHO
Adverse
Reaction
Terminology, required by EU) and COSTART (required by
FDA).
1989 -UK MCA ( Medicines Control Agency (UK))identifies need for a single
medical terminology to support new computer databases
•1991–ADROIT ( Adverse Drug Reactions Online Information Tracking )
medical terminology created by UK MCA
•January 1993 -identification of need for a medical terminology to support
European Community drug regulatory system
2Q 1993 -Working party set-up of European regulators and pharmaceutical
industry representatives to evaluate wider applicability of MCA
terminology
•November 1993 to October 1994 -Working party reviews and amends
MCA terminology, now called MedDRA
December 1993 -European Committee for Proprietary Medicinal Products
approves MedDRA Project.
•October 1994 -ICH recommends that MedDRA (version 1.0) should form
basis of a new medical terminology
November 1994 –ICH Steering Committee released a draft (alpha) version
(version 1.1) of terminology for review and evaluation .
•March 1995 –ICH working group evaluated the alpha test results and evaluated
suggested changes
February 1996 -MedDRA Version 1.5 released for review in US and Japan
•July 1997 –ICH approval of international terminology
November 1998 –IFPMA (Trustee of ICH Steering Committee, holder of
intellectual property) selected BDM International Inc. (a subsidiary of TRW Inc.)
as the Maintenance and Support Services Organization (MSSO)
•March 1999 –MedDRA version 2.1 released
Version

HLGT

HLT

PT

LLT

1.5

307

670

8,659

35,346

2.0 (1Q99)

334

1663

11,344

46,427

2.2 (3Q99)
3.0 (1QOO)

NA
334

1653

3.1 (2Q 00)
4.0 (June 01)

333

1652

332

7.1 (November,2004)
8.0 (March,05)
8.1 (August,2005)

54,107

1683

16,102

56,981

NA

6.0 (March03)

7.0 (March, 04)

15,149
NA

5.1 (September,02)

6.1 (September,03)

47,892

NA

4.1 (November 01)
5.0 (March, 02

12117

1632
332
332
332

16,293

60,518

NA
1681
1683

16,449

61,204

16,559

61,704

16,751

62,348

16,976

62,950
9.0 (March, 2006)

17,320

63,817

1682

17505

64,620

332

1682

17719
17,867

65,147

332

1,688 

18,075

66,135

18,209

66,587 

18483

67159

18641

67503

18,786 

68,258 

18,919 

68,661 

1,710 

19,086 

69,019 

1710
1,713

19294
19,550

69524
70,177

1713

19737

70634

20057

71236

332
9.1 (January, 2007)

10.0 ( April, 2007)
10.1(September 1, 2007 )
11.0 (March, 2008)
11.1 (1 September , 2008)
12.0 (March, 2009)
12.1 (September 2009)
13.0 (March 2010 )
13.1 (September 2010)
14.0 (March 2011) 

333

1699

335

1709

335

14.1 (1 September 2011 
15.0 ( March, 2012)
15.1 ( September, 2012)
16 ( March, 2013)

65,605

335
Conditions before MedDRA
 Use of different types of terminologies
Most organizations processing regulatory data used one of the international

adverse drug reaction terminologies in combination with
morbidity terminology.

Europe

United States

European Union
WHO-ART
ICD-9

Japan
J-ART
J-MEDIS

COSTART(C)
ICD-9-CM
Individualized Modified Terminologies to Suit Individual need.
Major Technical Lacunae:

 Lacked specificity of terms at the data entry level,
 Provided limited data retrieval options
(e.g., too few levels in the hierarchy, or capacity to retrieve data via one axis only),
and
 Ineffective handling of syndromes.
Solution:

Organizations with sufficient resources developed their
terminologies to address some or all of these deficiencies.

own

“in-house”
The use of multiple terminologies raised several problems:

 Use of different terminologies for various
cycle:

Phases of regulatory

Complicates data retrieval and analysis, making it difficult to cross-reference data.
For example, for Pre-registration clinical trials safety data had frequently been
classified by using ICD terminology and for post-marketing surveillance using JART, WHO-ART, or COSTART.

 Protracted International Communication:
Using different terminologies in separate geographic regions impaired international
communication and necessitated the conversion of data from one terminology to
another. This data conversion had the potential to cause time delays and loss or
distortion of data.
 The use of multiple terminologies also affected communication between
companies and clinical research organizations.
It became increasingly difficult to manage the information required for product
registration applications and to meet the time scale requirements for data
exchange between regulatory authorities and the medical product industries.
Scope of MedDRA
The MedDRA Terminology applies to all phases of drug
development (including biologicals but excluding animal toxicology).
It also applies to the health effects and malfunction of devices
(e.g., Catheter related infection and device leakage).
The categories of “medical” terms are as follows:
 symptoms

Although social circumstances are not usually regarded as medical terms,
they fall within signs
the “medical” scope if they are relevant to the evaluation

of regulatory data diseases
(e.g., in the assessment of clinical outcome of treatment in the light
 diagnoses
of exposure to 
risk factors).

therapeutic indications
 names and qualitative results of investigations,
Examples are:
including pharmacokinetics
the preferred term Foreign travel, the preferred term Occupational
 surgical and the high level terms
exposure to toxic agent and medical procedures Tobacco use and
Bereavement.  medical/social/family history
The above defined terminology, was developed for
regulators and the regulated medical product
industry.
data entry, retrieval,
evaluation and presentation, and in both pre- and postmarketing phases of the regulatory process as follows:
Hence, these groups can utilize the terminology for

clinical studies
reports of spontaneous adverse reactions and events
 regulatory submissions
regulated product information
Inclusion of terms from established terminologies
The MedDRA Terminology includes references to other terminologies
J-ART (1996)

Preferred Terms, Included Terms

COSTART (Fifth Edition

 Preferred Terms, Glossary Terms

WHO-ART© (3rd Quarter, 1998) 

Preferred Terms, Included Terms

 ICD-9
ICD-9-CM (4th revision)

Not Specified

HARTS (Release 2.2)

The terminology was not developed as a metathesaurus and the
hierarchies of these other terminologies are not subsets of it.
Thus, data entry terms from other terminologies do not necessarily have the same
PT (Preferred Term) in the MedDRA terminology as they did in their “parent”
terminology. The hierarchies used for data retrieval and presentation are unique to
the MedDRA.
Exclusion Criteria
The exclusion criteria used in the development of the terminology do not
necessarily limit the terminology’s expansion scope.

1. Since this is a medical terminology, the following terms used
in regulatory affairs are out of scope:

 Drug/product terminology
 Equipment/device/diagnostic product terminology
 Study design

 Demographics (including patient sex, age, race and religion)
2. As its focus is on health effects in individual patients, the
following are excluded:


Failure of devices

(except for a small number of clinically relevant terms)

Qualifiers that refer to populations rather than individual
patients, e.g., rare, frequent

Exclusion Criteria
3. Inclusion of terms is restricted to those within the scope of the
terminology as defined above. Thus, when terms from a particular field
(e.g., clinical pharmacology) are represented, only terms relevant to
regulatory affairs should be included.

4. Numerical values associated with parameters are not
included.

5. As a rule, descriptors of severity are not included in the
terminology.
Terms such as severe and mild are used only when
pertinent to the specificity of the term

(e.g., severe versus mild retardation).
OUT
IN
Diseases
Diagnoses
Signs
Drug product terms failure terms
Device
Symptoms
Therapeutic indications
Investigation Equipment, device,
names &
Numericalqualitative results
values for diagnostic product
terms
results
Medical & surgical procedures
Medical, social, family history
Medication Error
Terms study
Severity descriptorsfrom: design
Clinical trial
COSTARTterms
Population-level terms
Patient demographicqualifiers
WHO-ART©
HARTS
J-ART
MedDRA Term

vs.

MedDRA Code

MedDRA Term: a word(s)
Urticaria
MedDRA Code:

numbers representing each term
Urticaria

10046735
MedDRA Code
Unique numerical number assigned to each term in the
dictionary :

8 digits

•Starts with
alphabetically

10000001,

initially

started

•As terms added, codes assigned sequentially
•These are just identification numbers; they don’t
reflect the relational organization of the data files
(unlike WHO-ART)
Development Philosophy
• Based upon ANSI Z911 standard (American
National Standards Institute standard for
the development of a thesaurus)
• Provided structure for development and
future maintenance activities
• Chosen to ensure the product would support
the use of information technology
• Internationally recognized standard
34
Basic of Structural Elements
of the Terminology
Structural Elements of the Terminology
Relationships between terms in the terminology fall into the
following three categories:

1. Equivalence
The equivalence relationship groups synonymous
terms, or equivalent terms, under Preferred Terms.
2. Hierarchical
The hierarchy provides degrees or levels of
superordination and subordination. The superordinate
term is a broad grouping term applicable to each
subordinate descriptor linked to it.
3.Associative

Associative groupings of terms are linked horizontally in the
terminology.
Hierarchy
Hierarchies are an important mechanism for flexible
data retrieval and for the clear presentation of
data.
The five level hierarchy in this terminology provides
options for retrieving data by specific or broad
groupings, according to the level of specificity
required.
The Lowest Level Term (LLT) level provides maximum
specificity.
Hierarchy

System Organ Class (SOC)

Link

High Level Group Term (HLGT)

Vertical

High Level Term (HLT)

Preferred Term (PT)

Lowest Level Term (LLT)

SSC or SMQ

Detail discussion will be on
later phases of discussion
Example:

SOC
Blood and lymphatic system disorders

HLGT

White Blood Cell Disorder

HLT

Neutropenias

PT
Neutropenia

LLT
Neutropenia
aggravated

LLT
Neutropenia

SSC

Bone Marrow Depression
and Secondary
immunocompromised State
Example:

SOC
Cardiac Disorders

HLGT

Cardiac Arrhythmias

HLT

Rate and Rhythm of Disorders NEC

PT
Arrhythmia

LLT
Arrhythmia NOS

LLT
Arrhythmia

LLT (Non-current)

Other Specified Cardiac
Dysrhythmias

LLT
Dysrhythmias
System Organ Class (SOC)
Highest level of the hierarchy that

broadest concepts
for data retrieval.
provides the

SOCs identified or grouped by
Anatomical or physiological system or manifestation
site
(Gastrointestinal disorder)
Etiology (Infection of Infestation)
Purpose (Surgical and Medical procedure)
Anatomical or physiological system or manifestation site
or
Anatomy (Body System)

1.Blood and lymphatic system
disorders

9. Musculoskeletal and connective
tissue disorders
10. Nervous system disorders

2.Cardiac disorders

11. Psychiatric disorders

3.Ear and labyrinth disorders

12. Renal and urinary disorders

4.Endocrine disorders
5.Eye disorders
6.Gastrointestinal disorders
7.Hepatobiliary disorders
8.Immune system disorders

13. Reproductive system and breast
disorders
14. Respiratory, thoracic and mediastinal
disorders

15. Skin and subcutaneous tissue
disorders
16. Vascular disorders
Other (Cause/Association)
System Organ Class (SOC)

1.Congenital, familial and genetic
disorders

2.General disorders and
administration site conditions
3.Infections and infestations
4.Injury, poisoning and procedural

6. Metabolism and nutrition disorders
7. Neoplasms benign, malignant and
unspecified (including cysts and
polyps)
8. Pregnancy, puerperium and perinatal
conditions

complications
5.Investigations

9. Social circumstances
10. Surgical and medical procedures
Etiology-based SOCs

Supporting SOCs

1.Congenital, familial and genetic

1.Investigations

disorders

2.Social circumstances

2.Neoplasms benign, malignant and

3.Surgical and medical procedures

unspecified (including cysts and polyps)
3.Infections and infestations
High Level Group Term
( HLGT )
Subordinate
only
to
System
Organ
Classes
and
superordinate descriptor for one or more HLTs related to
anatomy, pathology, physiology, etiology or function.
SOC
Gastrointestinal disorders

HLGT
Dental and gingival
conditions

HLGT
Gastrointestinal
infections

HLGT
Gastrointestinal
vascular conditions
High Level Term (HLT)
Subordinate to HLGTs and super
descriptors for the PTs linked to it.

ordinate

Categories linked to PTs by anatomy, pathology,
physiology, etiology or function.
Used

solely

presentation

for
data retrieval
( not a coding level).

and
High Level Term
SOC
Gastrointestinal disorders
 

HLGT
Gastrointestinal infections  

HLT
Intestinal infections

HLT
Gastrointestinal infections,
site unspecified

HLT
Peritoneal infections
HLGT
Vascular Hypertensive Disorder  

HLT
Accelerated and malignant
Hypertension
HLT
Pregnancy Associated with
hypertension

HLT
Hypertension complication

HLT
Portal hypertension

HLT
Pulmonary hypertension
Preferred Term  

Each Preferred Term represents a single
medical concept:
• Clinical
pathologic
/etiologic
data
represented at PT level.
• Unambiguous, self- descriptive.
• No limit to the amount of LLTs that can be
associated with a single PT ( A PT must have at least
one LLT linked to it).

• When a new PT is added an identical LLT is created
automatically for data entry purposes.
• A PT must be linked to at least one SOC.
Each path to a SOC from a PT should have exactly one
HLT and HLGT (one route)
PT → HLT → HLGT → SOC

• PTs can be represented in multiple
SOCs (multiaxality)
• PTs may be groups with other PTs from the
same SOC or different SOCs in SSC for
cross hierarchy searches.
Example of PT
PT
Headache

LLT (Non-current)
LLT
Head Pain

LLT
Head Pressure

LLT
Head aggravated

Head dull

LLT
Head fullness

LLT

Headache

LLT

Head throbbing
Example of PT

PT
Dysponea

LLT (Non-current)
LLT
Air Hunger

LLT
Breath
Shortness

Breathlessness

LLT
Breathing Difficult
LLT

Dysponea

LLT

Difficult breathing
Lowest Level Term (LLT)
The most Specific level of terminology.
Facilitate the data transfer from other
terminologies.
Facilitate the data entry by subjective
choice.
Use for Auto coding.
Lowest Level Term (LLT)

Important Features:

Each LLT is linked to only one
preferred descriptor in the terminology.

PT;

this is its

Has one of the following relationships to the
Preferred Term (PT)

 Synonyms
 Lexical variants
 Quasi-synonym
 Sub-element
 Identical LLT
Synonyms
Different terms for the for the same descriptor

same concept inherent in the PT
For Example:

PT
Arthritis

LLT
Joint Inflammation
Lexical variants
Different word forms for the same expression
These include
full names vs. abbreviations
For Example:
PT
Acquired immunodeficiency
syndrome

LLT
AIDS

OR

direct vs. inverted word order
PT
Biopsy tongue

LLT
Tongue biopsy
Quasi-synonym
Terms that are not precisely the same meaning as
another term, but are treated as synonymous in a
given terminology.

PT
Otitis externa

LLT
Bilateral otitis externa

Based on site and laterality
descriptions
both
the
terms are considered as
Synonymous or equivalent
clinically
for
medical
product
regulatory
purposes.
Sub-element
Sub-elements (of the parent PT) are represented by LLTs
with more detailed information such as anatomic specificity.
PT
Contusion

LLT
Bruising of face

LLT
Bruising of leg
Identical LLT
One LLT is identical to its PT for data entry purposes
PT
Arrhythmia

LLT
Arrhythmia NOS

LLT
Arrhythmia

LLT (Non-current)

Other Specified Cardiac
Dysrhythmias

LLT
Dysrhythmias

PT
Dementia Alzheimer’s type

LLT
Dementia Alzheimer’s type

In these instance, the LLT and parent
PT have the same MedDRA code but
appear at both levels.
Basic Rules in MedDRA
PT: British Spelling
LLT: British and American Spelling
Medical Term: Dorland’s Medical
Dictionary (29th Ed)
Non-Medical Term: Merrian-Webster
English Dictionary (29th Ed)
Thank you
But First, Some Definitions
• Controlled vocabulary: a bunch of words, no relationships
– But there is advantage if all users use the same terms to
describe things

• Taxonomy: is a controlled vocabulary with hierarchy
• Thesaurus: is interchangeable with controlled vocabulary,
also sometimes referred to as an ontology
• Ontology: all of the above; think neural network with a
bunch of relationships
• MetaData: data about data (I really hate this definition, but
it’s accurate)
•

MetaThesaurus – a collection of all of these things

– EXAMPLE: UMLS
UMLS – Unified Medical Language
System
• More than 5 million terms or named entities
• Divided into concepts, and each term has
unique identifier
• Not a vocabulary, but a mapping BETWEEN
vocabularies
• Vocabularies included in the UMLS:
–
–
–
–

MeSH Headings in 8 languages (MeSH = Medical Subject Headings)
ICPC-93 in 14 languages (ICPC = International Classification of Primary Care)
WHO Adverse Drug Reaction Terminology in 5 languages
SNOMED-2, SNOMED-3, and UK Clinical Terms (former Read Codes) (SNOMED
= Systemized Nomenclature of Medicine)
– ICD-10 in English and German (ICD = International Classification of Diseases)

Más contenido relacionado

La actualidad más candente

Expedited report criteria in pharmacovigilance by isa hassan abubakar
Expedited report criteria in pharmacovigilance by isa hassan abubakarExpedited report criteria in pharmacovigilance by isa hassan abubakar
Expedited report criteria in pharmacovigilance by isa hassan abubakarISAHASSANABUBAKAR
 
Pharmacovigilance signal and signal detection
Pharmacovigilance signal and signal detectionPharmacovigilance signal and signal detection
Pharmacovigilance signal and signal detectionKiranRajput38
 
Pharmacovigilance program of India (PvPI)
Pharmacovigilance program of India (PvPI)Pharmacovigilance program of India (PvPI)
Pharmacovigilance program of India (PvPI)SnehaKhandale1
 
Pharmacovigilance and ICH guidlines
Pharmacovigilance and ICH guidlinesPharmacovigilance and ICH guidlines
Pharmacovigilance and ICH guidlineschandroo80
 
INTERNATIONAL NON PROPRIETARY NAMES FOR DRUGS1.pptx
INTERNATIONAL NON PROPRIETARY NAMES FOR DRUGS1.pptxINTERNATIONAL NON PROPRIETARY NAMES FOR DRUGS1.pptx
INTERNATIONAL NON PROPRIETARY NAMES FOR DRUGS1.pptxE Poovarasan
 
WHO International Drug Monitoring Program
WHO International Drug Monitoring ProgramWHO International Drug Monitoring Program
WHO International Drug Monitoring ProgramSnehaKhandale1
 
MedDRA Coding - Katalyst HLS
MedDRA Coding - Katalyst HLSMedDRA Coding - Katalyst HLS
MedDRA Coding - Katalyst HLSKatalyst HLS
 
Methods of causality assessment
Methods of causality assessmentMethods of causality assessment
Methods of causality assessmentthennarasu palani
 
ICH E2A GUIDELINE
ICH E2A GUIDELINEICH E2A GUIDELINE
ICH E2A GUIDELINEsathishat9
 
Aggregate Reporting_Pharmacovigilance_Katalyst HLS
Aggregate Reporting_Pharmacovigilance_Katalyst HLSAggregate Reporting_Pharmacovigilance_Katalyst HLS
Aggregate Reporting_Pharmacovigilance_Katalyst HLSKatalyst HLS
 
The relevance of the Purple Book for current debates
The relevance of the Purple Book for current debatesThe relevance of the Purple Book for current debates
The relevance of the Purple Book for current debatesTHL
 
Pharmacovigilance Overview
Pharmacovigilance OverviewPharmacovigilance Overview
Pharmacovigilance OverviewSivasankaranV
 

La actualidad más candente (20)

Cro
CroCro
Cro
 
Expedited report criteria in pharmacovigilance by isa hassan abubakar
Expedited report criteria in pharmacovigilance by isa hassan abubakarExpedited report criteria in pharmacovigilance by isa hassan abubakar
Expedited report criteria in pharmacovigilance by isa hassan abubakar
 
PSUR
PSURPSUR
PSUR
 
Pharmacovigilance signal and signal detection
Pharmacovigilance signal and signal detectionPharmacovigilance signal and signal detection
Pharmacovigilance signal and signal detection
 
Pharmacovigilance program of India (PvPI)
Pharmacovigilance program of India (PvPI)Pharmacovigilance program of India (PvPI)
Pharmacovigilance program of India (PvPI)
 
Safety Data Generation
Safety Data GenerationSafety Data Generation
Safety Data Generation
 
Pharmacovigilance and ICH guidlines
Pharmacovigilance and ICH guidlinesPharmacovigilance and ICH guidlines
Pharmacovigilance and ICH guidlines
 
Pharmacovigilance methods
Pharmacovigilance methodsPharmacovigilance methods
Pharmacovigilance methods
 
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADR’S
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADR’SSEVERITY AND SERIOUSNESS ASSESSMENT OF ADR’S
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADR’S
 
INTERNATIONAL NON PROPRIETARY NAMES FOR DRUGS1.pptx
INTERNATIONAL NON PROPRIETARY NAMES FOR DRUGS1.pptxINTERNATIONAL NON PROPRIETARY NAMES FOR DRUGS1.pptx
INTERNATIONAL NON PROPRIETARY NAMES FOR DRUGS1.pptx
 
WHO International Drug Monitoring Program
WHO International Drug Monitoring ProgramWHO International Drug Monitoring Program
WHO International Drug Monitoring Program
 
MedDRA Coding - Katalyst HLS
MedDRA Coding - Katalyst HLSMedDRA Coding - Katalyst HLS
MedDRA Coding - Katalyst HLS
 
Vaccine pharmacovigilance _ rajiv ahlawat
Vaccine pharmacovigilance _ rajiv ahlawatVaccine pharmacovigilance _ rajiv ahlawat
Vaccine pharmacovigilance _ rajiv ahlawat
 
Methods of causality assessment
Methods of causality assessmentMethods of causality assessment
Methods of causality assessment
 
Adverse drug reactions
Adverse drug reactionsAdverse drug reactions
Adverse drug reactions
 
ICH E2A GUIDELINE
ICH E2A GUIDELINEICH E2A GUIDELINE
ICH E2A GUIDELINE
 
Aggregate Reporting_Pharmacovigilance_Katalyst HLS
Aggregate Reporting_Pharmacovigilance_Katalyst HLSAggregate Reporting_Pharmacovigilance_Katalyst HLS
Aggregate Reporting_Pharmacovigilance_Katalyst HLS
 
The relevance of the Purple Book for current debates
The relevance of the Purple Book for current debatesThe relevance of the Purple Book for current debates
The relevance of the Purple Book for current debates
 
Pharmacovigilance Overview
Pharmacovigilance OverviewPharmacovigilance Overview
Pharmacovigilance Overview
 
ICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand Pirouzi
ICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand PirouziICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand Pirouzi
ICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand Pirouzi
 

Destacado

MedDRA Point to consider
MedDRA Point to consider MedDRA Point to consider
MedDRA Point to consider Somnath Mondal
 
Working with Argus Safety in a Global Community
Working with Argus Safety in a Global CommunityWorking with Argus Safety in a Global Community
Working with Argus Safety in a Global CommunityPerficient
 
Best Practices on Medical Coding in MedDRA
Best Practices on Medical Coding in MedDRABest Practices on Medical Coding in MedDRA
Best Practices on Medical Coding in MedDRAPerficient
 
Drug Safety And Pharmacovigilance
Drug Safety And PharmacovigilanceDrug Safety And Pharmacovigilance
Drug Safety And PharmacovigilanceJohn Robinson
 
Safety and Pharmacovigilance System: Oracle Argus Safety Suite
Safety and Pharmacovigilance System: Oracle Argus Safety SuiteSafety and Pharmacovigilance System: Oracle Argus Safety Suite
Safety and Pharmacovigilance System: Oracle Argus Safety SuitePerficient
 
Integrating Oracle Argus Safety with other Clinical Systems Using Argus Inter...
Integrating Oracle Argus Safety with other Clinical Systems Using Argus Inter...Integrating Oracle Argus Safety with other Clinical Systems Using Argus Inter...
Integrating Oracle Argus Safety with other Clinical Systems Using Argus Inter...Perficient
 
Using JReview to Analyze Clinical and Pharmacovigilance Data in Disparate Sys...
Using JReview to Analyze Clinical and Pharmacovigilance Data in Disparate Sys...Using JReview to Analyze Clinical and Pharmacovigilance Data in Disparate Sys...
Using JReview to Analyze Clinical and Pharmacovigilance Data in Disparate Sys...Perficient, Inc.
 
Black chapter of biomedical research
Black chapter of biomedical researchBlack chapter of biomedical research
Black chapter of biomedical researchWeam Banjar
 
Phase ii study of temozolomide and thalidomide
Phase ii study of temozolomide and thalidomidePhase ii study of temozolomide and thalidomide
Phase ii study of temozolomide and thalidomideseayat1103
 
Features of a World-Class Safety System
Features of a World-Class Safety SystemFeatures of a World-Class Safety System
Features of a World-Class Safety SystemPerficient, Inc.
 
Oracle argus safety installation implementation
Oracle argus safety installation implementationOracle argus safety installation implementation
Oracle argus safety installation implementationDr.K Pati
 
Vigi flow -_data_entry
Vigi flow -_data_entryVigi flow -_data_entry
Vigi flow -_data_entrySomnath Mondal
 
Clinical Trials Market - India - Sample
Clinical Trials Market - India - SampleClinical Trials Market - India - Sample
Clinical Trials Market - India - SampleNetscribes, Inc.
 
How Oracle Argus Safety 8.x Supports Product Safety Needs
How Oracle Argus Safety 8.x Supports Product Safety NeedsHow Oracle Argus Safety 8.x Supports Product Safety Needs
How Oracle Argus Safety 8.x Supports Product Safety NeedsPerficient, Inc.
 
Best practices in pharmacovigilance Services by HySynth biotechnologies
Best practices in pharmacovigilance Services by HySynth biotechnologiesBest practices in pharmacovigilance Services by HySynth biotechnologies
Best practices in pharmacovigilance Services by HySynth biotechnologiesSaravanan Subramanian (SAS)
 
Medical Coding textbook for beginners
Medical Coding textbook for beginnersMedical Coding textbook for beginners
Medical Coding textbook for beginnersBeth Rich
 
Data mining in pharmacovigilance
Data mining in pharmacovigilanceData mining in pharmacovigilance
Data mining in pharmacovigilanceBhaswat Chakraborty
 
Pharmacovigilance Practice In
Pharmacovigilance Practice InPharmacovigilance Practice In
Pharmacovigilance Practice Inclarityeye
 

Destacado (20)

MedDRA Point to consider
MedDRA Point to consider MedDRA Point to consider
MedDRA Point to consider
 
Working with Argus Safety in a Global Community
Working with Argus Safety in a Global CommunityWorking with Argus Safety in a Global Community
Working with Argus Safety in a Global Community
 
Best Practices on Medical Coding in MedDRA
Best Practices on Medical Coding in MedDRABest Practices on Medical Coding in MedDRA
Best Practices on Medical Coding in MedDRA
 
Drug Safety And Pharmacovigilance
Drug Safety And PharmacovigilanceDrug Safety And Pharmacovigilance
Drug Safety And Pharmacovigilance
 
Safety and Pharmacovigilance System: Oracle Argus Safety Suite
Safety and Pharmacovigilance System: Oracle Argus Safety SuiteSafety and Pharmacovigilance System: Oracle Argus Safety Suite
Safety and Pharmacovigilance System: Oracle Argus Safety Suite
 
Integrating Oracle Argus Safety with other Clinical Systems Using Argus Inter...
Integrating Oracle Argus Safety with other Clinical Systems Using Argus Inter...Integrating Oracle Argus Safety with other Clinical Systems Using Argus Inter...
Integrating Oracle Argus Safety with other Clinical Systems Using Argus Inter...
 
Using JReview to Analyze Clinical and Pharmacovigilance Data in Disparate Sys...
Using JReview to Analyze Clinical and Pharmacovigilance Data in Disparate Sys...Using JReview to Analyze Clinical and Pharmacovigilance Data in Disparate Sys...
Using JReview to Analyze Clinical and Pharmacovigilance Data in Disparate Sys...
 
Black chapter of biomedical research
Black chapter of biomedical researchBlack chapter of biomedical research
Black chapter of biomedical research
 
Phase ii study of temozolomide and thalidomide
Phase ii study of temozolomide and thalidomidePhase ii study of temozolomide and thalidomide
Phase ii study of temozolomide and thalidomide
 
Features of a World-Class Safety System
Features of a World-Class Safety SystemFeatures of a World-Class Safety System
Features of a World-Class Safety System
 
Anuja PV
Anuja PVAnuja PV
Anuja PV
 
Oracle argus safety installation implementation
Oracle argus safety installation implementationOracle argus safety installation implementation
Oracle argus safety installation implementation
 
Vigi flow -_data_entry
Vigi flow -_data_entryVigi flow -_data_entry
Vigi flow -_data_entry
 
Clinical Trials Market - India - Sample
Clinical Trials Market - India - SampleClinical Trials Market - India - Sample
Clinical Trials Market - India - Sample
 
How Oracle Argus Safety 8.x Supports Product Safety Needs
How Oracle Argus Safety 8.x Supports Product Safety NeedsHow Oracle Argus Safety 8.x Supports Product Safety Needs
How Oracle Argus Safety 8.x Supports Product Safety Needs
 
Best practices in pharmacovigilance Services by HySynth biotechnologies
Best practices in pharmacovigilance Services by HySynth biotechnologiesBest practices in pharmacovigilance Services by HySynth biotechnologies
Best practices in pharmacovigilance Services by HySynth biotechnologies
 
Medical Coding textbook for beginners
Medical Coding textbook for beginnersMedical Coding textbook for beginners
Medical Coding textbook for beginners
 
HySynth Pharmacovigilance
HySynth PharmacovigilanceHySynth Pharmacovigilance
HySynth Pharmacovigilance
 
Data mining in pharmacovigilance
Data mining in pharmacovigilanceData mining in pharmacovigilance
Data mining in pharmacovigilance
 
Pharmacovigilance Practice In
Pharmacovigilance Practice InPharmacovigilance Practice In
Pharmacovigilance Practice In
 

Similar a Med dra Basics

Med ra terminology
Med ra terminologyMed ra terminology
Med ra terminologycrtutor
 
CTD and E-CTD Regulatory Affairs
CTD and E-CTD Regulatory AffairsCTD and E-CTD Regulatory Affairs
CTD and E-CTD Regulatory AffairsDipesh Gosavi
 
FDA and Electronic Common Technical Document - By Compliance Global Inc
FDA and Electronic Common Technical Document - By Compliance Global IncFDA and Electronic Common Technical Document - By Compliance Global Inc
FDA and Electronic Common Technical Document - By Compliance Global IncCompliance Global Inc
 
Information on Pharmacovigilance.pptx
Information on Pharmacovigilance.pptxInformation on Pharmacovigilance.pptx
Information on Pharmacovigilance.pptxImmanuel Jebastine M
 
International Overview & Future Medical Devices Regulations
International Overview & Future   Medical Devices RegulationsInternational Overview & Future   Medical Devices Regulations
International Overview & Future Medical Devices Regulationsmdbio2009
 
Clinical evaluation report cer in a more stringent regulatory- Pepgra Healthcare
Clinical evaluation report cer in a more stringent regulatory- Pepgra HealthcareClinical evaluation report cer in a more stringent regulatory- Pepgra Healthcare
Clinical evaluation report cer in a more stringent regulatory- Pepgra HealthcarePEPGRA Healthcare
 
ICH GUIDELINES MULTIDISCIPLINARY
ICH GUIDELINES MULTIDISCIPLINARYICH GUIDELINES MULTIDISCIPLINARY
ICH GUIDELINES MULTIDISCIPLINARYHARIBABUC2
 
Common Technical Document
Common Technical DocumentCommon Technical Document
Common Technical DocumentDr Sukanta sen
 
FDA and Electronic Common Technical Document -By Compliance Global Inc
FDA and Electronic Common Technical Document -By Compliance Global IncFDA and Electronic Common Technical Document -By Compliance Global Inc
FDA and Electronic Common Technical Document -By Compliance Global IncCompliance Global Inc
 
Utilization of Medical Devices Standards to Demonstrate Safety
Utilization of Medical Devices Standards to Demonstrate SafetyUtilization of Medical Devices Standards to Demonstrate Safety
Utilization of Medical Devices Standards to Demonstrate SafetyUN SPHS
 
ICH Guidelines for Pharmacovigilance
ICH Guidelines for PharmacovigilanceICH Guidelines for Pharmacovigilance
ICH Guidelines for PharmacovigilanceDr. Ramesh Bhandari
 
Organ Preservation Market PPT: Demand, Trends and Business Opportunities 2022-27
Organ Preservation Market PPT: Demand, Trends and Business Opportunities 2022-27Organ Preservation Market PPT: Demand, Trends and Business Opportunities 2022-27
Organ Preservation Market PPT: Demand, Trends and Business Opportunities 2022-27IMARC Group
 
cmc [ chemistry manufacturing control ]
cmc [ chemistry manufacturing control ]cmc [ chemistry manufacturing control ]
cmc [ chemistry manufacturing control ]Akshay Patil
 

Similar a Med dra Basics (20)

Med ra terminology
Med ra terminologyMed ra terminology
Med ra terminology
 
CTD & ectd.pptx
CTD & ectd.pptxCTD & ectd.pptx
CTD & ectd.pptx
 
CTD and E-CTD Regulatory Affairs
CTD and E-CTD Regulatory AffairsCTD and E-CTD Regulatory Affairs
CTD and E-CTD Regulatory Affairs
 
Medical devices
Medical devicesMedical devices
Medical devices
 
ICH
ICHICH
ICH
 
Ctd and e ctd
Ctd and e ctdCtd and e ctd
Ctd and e ctd
 
FDA and Electronic Common Technical Document - By Compliance Global Inc
FDA and Electronic Common Technical Document - By Compliance Global IncFDA and Electronic Common Technical Document - By Compliance Global Inc
FDA and Electronic Common Technical Document - By Compliance Global Inc
 
160428_WP_Medical_UDI_EN.PDF
160428_WP_Medical_UDI_EN.PDF160428_WP_Medical_UDI_EN.PDF
160428_WP_Medical_UDI_EN.PDF
 
Information on Pharmacovigilance.pptx
Information on Pharmacovigilance.pptxInformation on Pharmacovigilance.pptx
Information on Pharmacovigilance.pptx
 
CTD and eCTD.pptx
CTD and eCTD.pptxCTD and eCTD.pptx
CTD and eCTD.pptx
 
International Overview & Future Medical Devices Regulations
International Overview & Future   Medical Devices RegulationsInternational Overview & Future   Medical Devices Regulations
International Overview & Future Medical Devices Regulations
 
Clinical evaluation report cer in a more stringent regulatory- Pepgra Healthcare
Clinical evaluation report cer in a more stringent regulatory- Pepgra HealthcareClinical evaluation report cer in a more stringent regulatory- Pepgra Healthcare
Clinical evaluation report cer in a more stringent regulatory- Pepgra Healthcare
 
ICH GUIDELINES MULTIDISCIPLINARY
ICH GUIDELINES MULTIDISCIPLINARYICH GUIDELINES MULTIDISCIPLINARY
ICH GUIDELINES MULTIDISCIPLINARY
 
Common Technical Document
Common Technical DocumentCommon Technical Document
Common Technical Document
 
FDA and Electronic Common Technical Document -By Compliance Global Inc
FDA and Electronic Common Technical Document -By Compliance Global IncFDA and Electronic Common Technical Document -By Compliance Global Inc
FDA and Electronic Common Technical Document -By Compliance Global Inc
 
ICH GUIDELINES
ICH GUIDELINESICH GUIDELINES
ICH GUIDELINES
 
Utilization of Medical Devices Standards to Demonstrate Safety
Utilization of Medical Devices Standards to Demonstrate SafetyUtilization of Medical Devices Standards to Demonstrate Safety
Utilization of Medical Devices Standards to Demonstrate Safety
 
ICH Guidelines for Pharmacovigilance
ICH Guidelines for PharmacovigilanceICH Guidelines for Pharmacovigilance
ICH Guidelines for Pharmacovigilance
 
Organ Preservation Market PPT: Demand, Trends and Business Opportunities 2022-27
Organ Preservation Market PPT: Demand, Trends and Business Opportunities 2022-27Organ Preservation Market PPT: Demand, Trends and Business Opportunities 2022-27
Organ Preservation Market PPT: Demand, Trends and Business Opportunities 2022-27
 
cmc [ chemistry manufacturing control ]
cmc [ chemistry manufacturing control ]cmc [ chemistry manufacturing control ]
cmc [ chemistry manufacturing control ]
 

Último

Textual Evidence in Reading and Writing of SHS
Textual Evidence in Reading and Writing of SHSTextual Evidence in Reading and Writing of SHS
Textual Evidence in Reading and Writing of SHSMae Pangan
 
Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Celine George
 
THEORIES OF ORGANIZATION-PUBLIC ADMINISTRATION
THEORIES OF ORGANIZATION-PUBLIC ADMINISTRATIONTHEORIES OF ORGANIZATION-PUBLIC ADMINISTRATION
THEORIES OF ORGANIZATION-PUBLIC ADMINISTRATIONHumphrey A Beña
 
4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptx4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptxmary850239
 
AUDIENCE THEORY -CULTIVATION THEORY - GERBNER.pptx
AUDIENCE THEORY -CULTIVATION THEORY -  GERBNER.pptxAUDIENCE THEORY -CULTIVATION THEORY -  GERBNER.pptx
AUDIENCE THEORY -CULTIVATION THEORY - GERBNER.pptxiammrhaywood
 
Activity 2-unit 2-update 2024. English translation
Activity 2-unit 2-update 2024. English translationActivity 2-unit 2-update 2024. English translation
Activity 2-unit 2-update 2024. English translationRosabel UA
 
4.16.24 Poverty and Precarity--Desmond.pptx
4.16.24 Poverty and Precarity--Desmond.pptx4.16.24 Poverty and Precarity--Desmond.pptx
4.16.24 Poverty and Precarity--Desmond.pptxmary850239
 
Daily Lesson Plan in Mathematics Quarter 4
Daily Lesson Plan in Mathematics Quarter 4Daily Lesson Plan in Mathematics Quarter 4
Daily Lesson Plan in Mathematics Quarter 4JOYLYNSAMANIEGO
 
Transaction Management in Database Management System
Transaction Management in Database Management SystemTransaction Management in Database Management System
Transaction Management in Database Management SystemChristalin Nelson
 
GRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTS
GRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTSGRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTS
GRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTSJoshuaGantuangco2
 
Dust Of Snow By Robert Frost Class-X English CBSE
Dust Of Snow By Robert Frost Class-X English CBSEDust Of Snow By Robert Frost Class-X English CBSE
Dust Of Snow By Robert Frost Class-X English CBSEaurabinda banchhor
 
Keynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designKeynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designMIPLM
 
Measures of Position DECILES for ungrouped data
Measures of Position DECILES for ungrouped dataMeasures of Position DECILES for ungrouped data
Measures of Position DECILES for ungrouped dataBabyAnnMotar
 
ICS2208 Lecture6 Notes for SL spaces.pdf
ICS2208 Lecture6 Notes for SL spaces.pdfICS2208 Lecture6 Notes for SL spaces.pdf
ICS2208 Lecture6 Notes for SL spaces.pdfVanessa Camilleri
 
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptxMULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptxAnupkumar Sharma
 
Q4-PPT-Music9_Lesson-1-Romantic-Opera.pptx
Q4-PPT-Music9_Lesson-1-Romantic-Opera.pptxQ4-PPT-Music9_Lesson-1-Romantic-Opera.pptx
Q4-PPT-Music9_Lesson-1-Romantic-Opera.pptxlancelewisportillo
 
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)lakshayb543
 
How to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPHow to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPCeline George
 

Último (20)

Textual Evidence in Reading and Writing of SHS
Textual Evidence in Reading and Writing of SHSTextual Evidence in Reading and Writing of SHS
Textual Evidence in Reading and Writing of SHS
 
Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17
 
THEORIES OF ORGANIZATION-PUBLIC ADMINISTRATION
THEORIES OF ORGANIZATION-PUBLIC ADMINISTRATIONTHEORIES OF ORGANIZATION-PUBLIC ADMINISTRATION
THEORIES OF ORGANIZATION-PUBLIC ADMINISTRATION
 
4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptx4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptx
 
AUDIENCE THEORY -CULTIVATION THEORY - GERBNER.pptx
AUDIENCE THEORY -CULTIVATION THEORY -  GERBNER.pptxAUDIENCE THEORY -CULTIVATION THEORY -  GERBNER.pptx
AUDIENCE THEORY -CULTIVATION THEORY - GERBNER.pptx
 
Activity 2-unit 2-update 2024. English translation
Activity 2-unit 2-update 2024. English translationActivity 2-unit 2-update 2024. English translation
Activity 2-unit 2-update 2024. English translation
 
4.16.24 Poverty and Precarity--Desmond.pptx
4.16.24 Poverty and Precarity--Desmond.pptx4.16.24 Poverty and Precarity--Desmond.pptx
4.16.24 Poverty and Precarity--Desmond.pptx
 
FINALS_OF_LEFT_ON_C'N_EL_DORADO_2024.pptx
FINALS_OF_LEFT_ON_C'N_EL_DORADO_2024.pptxFINALS_OF_LEFT_ON_C'N_EL_DORADO_2024.pptx
FINALS_OF_LEFT_ON_C'N_EL_DORADO_2024.pptx
 
Daily Lesson Plan in Mathematics Quarter 4
Daily Lesson Plan in Mathematics Quarter 4Daily Lesson Plan in Mathematics Quarter 4
Daily Lesson Plan in Mathematics Quarter 4
 
Transaction Management in Database Management System
Transaction Management in Database Management SystemTransaction Management in Database Management System
Transaction Management in Database Management System
 
GRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTS
GRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTSGRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTS
GRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTS
 
Dust Of Snow By Robert Frost Class-X English CBSE
Dust Of Snow By Robert Frost Class-X English CBSEDust Of Snow By Robert Frost Class-X English CBSE
Dust Of Snow By Robert Frost Class-X English CBSE
 
Keynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designKeynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-design
 
Measures of Position DECILES for ungrouped data
Measures of Position DECILES for ungrouped dataMeasures of Position DECILES for ungrouped data
Measures of Position DECILES for ungrouped data
 
ICS2208 Lecture6 Notes for SL spaces.pdf
ICS2208 Lecture6 Notes for SL spaces.pdfICS2208 Lecture6 Notes for SL spaces.pdf
ICS2208 Lecture6 Notes for SL spaces.pdf
 
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptxMULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
 
YOUVE GOT EMAIL_FINALS_EL_DORADO_2024.pptx
YOUVE GOT EMAIL_FINALS_EL_DORADO_2024.pptxYOUVE GOT EMAIL_FINALS_EL_DORADO_2024.pptx
YOUVE GOT EMAIL_FINALS_EL_DORADO_2024.pptx
 
Q4-PPT-Music9_Lesson-1-Romantic-Opera.pptx
Q4-PPT-Music9_Lesson-1-Romantic-Opera.pptxQ4-PPT-Music9_Lesson-1-Romantic-Opera.pptx
Q4-PPT-Music9_Lesson-1-Romantic-Opera.pptx
 
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
 
How to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPHow to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERP
 

Med dra Basics

  • 1. By MedDRA Basics Somnath Mondal Technical Associate (PVPI) Dept. of Clinical & Experimental Pharmacology School of tropical Medicine, Kolkata Dated 20th Nov continuance from 7th Nov,2013
  • 2. Agenda 1. Introduction to MedDRA 2. ABC of Coding 3. Brief History of MedDRA Development 4. Scope of MedDRA 5. MedDRA Term vs. MedDRA Code 6. Basic of Structural Elements of the Terminology
  • 3. What is MedDRA? Med = Medical D = Dictionary R = Regulatory A = Activities
  • 4. MedDRA Definition MedDRA is a clinically-validated international medical terminology used by regulatory authorities and the regulated biopharmaceutical industry. The terminology is used through the entire regulatory process, from pre-marketing to post-marketing, and for data entry, retrieval, evaluation, and presentation.
  • 5. Requirements for MedDRA development • International applicability • Supported and used by both industry and regulators • Broader coverage of health data • Increased specificity • Structure to support analysis and presentation • Centrally and externally maintained • Compatible with IT systems and tools
  • 6. Rationale For MedDRA Global Standardization and Universal Harmonization Across Regulatory Agencies Across Multinational Pharmaceutical Companies Necessary through out Product Life Cycle Necessary for Electronic Data Transfer Avoid Translation Distortions and Errors Across Countries Save Time: No need to cross reference through life time of product. No need to Translate Provide a classification for a wide range of clinical information, able to support for multiple medical product areas
  • 7. Who participates in the MedDRA ? Representatives of Authorities and Pharmaceutical Companies from : Europe Japan United States European Union All reports (electronic) – January 2003  EudraCT SUSARs  Starting 2003 all severe single case safety reports going back to 1995 must be electronically submitted before the start of 2004.  Internal adverse event database Japanese Ministry of Health, Labour and Welfare  Required use of MedDRA for electronic filing start 1 October 2003  Proposed Rule for Safety Reporting Requirements (2003): FDA proposes to use MedDRA for post marketing safety reports MedDRA to be used in Periodic Infection & Safety Reports from April 2004 Observers: WHO, European Free Trade Association (EFTA), Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden, Greenland), Canada, Australia
  • 8. Sample of Current Regulators MedDRA
  • 10. Why Do Medical and Drug Terms Need to Be Classified? Investigators report the same medical and treatment terms (called verbatim terms) in many different ways on the CRF/ ADR Reporting Form. In order to compare the frequency of adverse events in drug treatment versus non treatment groups the terms need to be classified into standardized terminology.
  • 11. Why? • To facilitate the aggregation of verbatim reports into medically meaningful groupings so that they can be reviewed, analysed and communicated to the regulatory authorities. • To ensure the accurate, unbiased & consistent classification of CRF verbatim terms as reported by the investigators
  • 12. What is Coding? Etymology: L, caudex, book The process of organizing information into categories, which are assigned codes for the purposes of sorting, storing, and retrieving the data. The process of transforming qualitative data into numerical data that can be entered into a computer file. Medical coding is essentially the process of assigning formal, standardized medical codes to patient medical records.
  • 13. Why is Medical Coding? Medical coding is the transformation of narrative descriptions of diseases, injuries, and healthcare procedures into numeric or alphanumeric designations (that is, code numbers). The code numbers are detailed in order to Accurately describe the diagnoses (that is, what is wrong with the patient). and The procedures performed to test or correct these diagnoses. Because medicine is not always an exact science, codes were developed to identify all reasons for seeking healthcare.
  • 14. Why do Medical Coding? If we search for "medical coding" on web , we will be driven to websites which deals with the ICD (9,10 etc.), CPT (Current Procedural Terminology) or HCPCS ( Healthcare Common Procedure Coding System) medical coding particularly deals with mapping various medical diagnosis and procedures to codes. Common uses of medical codes in healthcare include: Identifying symptoms that must be evaluated and to alert other healthcare professionals to life-threatening allergies. The services performed for reimbursement ReportingICD or CPT coding is out of scope here in this presentation. Helping with administrative functions such as staffing, scheduling, and adding or decreasing healthcare services Comparing facilities and planning for new services in underserved areas These mostly deals with medical insurance data and medical billing which is different from the coding in all phases of drug development.
  • 15. Coding decisions during all phases of drug development directly impact submissions for New Drug Applications (NDAs), safety surveillance and product labelling. The success of a submission to the concerned regulatory authority (e.g. USFDA, EMEA or DCGI?) can be significantly impacted by the analysis of adverse events, medical history and concomitant medications. The analysis relies on the interpretation of what has been transcribed from the subject CRF (Case Report Form) or ADR reporting form. Ultimately, medical coding data permits access to health records according The coding of patient data is critical in the grouping, analysis, and to diagnoses and procedures for use in clinical care, research, education reporting of data. and for regulatory activities.
  • 16. Brief History of MedDRA Development
  • 17. Pre-MedDRA Era The essentiality and importance for an internationally accepted medical terminology, classification system was recognized at the First International Statistical Conference in Brussels in 1853 to evaluate medical data statistically to optimize and regulate public health issues globally. The standardization effort bore fruit in 1969 with the FDA’s use of the COSTART (Coding Symbols for a Thesaurus of Adverse Reaction Terms) dictionary. For the next quarter century, adverse event coding was dominated by WHOART (WHO Adverse Reaction Terminology, required by EU) and COSTART (required by FDA).
  • 18. 1989 -UK MCA ( Medicines Control Agency (UK))identifies need for a single medical terminology to support new computer databases •1991–ADROIT ( Adverse Drug Reactions Online Information Tracking ) medical terminology created by UK MCA •January 1993 -identification of need for a medical terminology to support European Community drug regulatory system 2Q 1993 -Working party set-up of European regulators and pharmaceutical industry representatives to evaluate wider applicability of MCA terminology •November 1993 to October 1994 -Working party reviews and amends MCA terminology, now called MedDRA December 1993 -European Committee for Proprietary Medicinal Products approves MedDRA Project. •October 1994 -ICH recommends that MedDRA (version 1.0) should form basis of a new medical terminology
  • 19. November 1994 –ICH Steering Committee released a draft (alpha) version (version 1.1) of terminology for review and evaluation . •March 1995 –ICH working group evaluated the alpha test results and evaluated suggested changes February 1996 -MedDRA Version 1.5 released for review in US and Japan •July 1997 –ICH approval of international terminology November 1998 –IFPMA (Trustee of ICH Steering Committee, holder of intellectual property) selected BDM International Inc. (a subsidiary of TRW Inc.) as the Maintenance and Support Services Organization (MSSO) •March 1999 –MedDRA version 2.1 released
  • 20. Version HLGT HLT PT LLT 1.5 307 670 8,659 35,346 2.0 (1Q99) 334 1663 11,344 46,427 2.2 (3Q99) 3.0 (1QOO) NA 334 1653 3.1 (2Q 00) 4.0 (June 01) 333 1652 332 7.1 (November,2004) 8.0 (March,05) 8.1 (August,2005) 54,107 1683 16,102 56,981 NA 6.0 (March03) 7.0 (March, 04) 15,149 NA 5.1 (September,02) 6.1 (September,03) 47,892 NA 4.1 (November 01) 5.0 (March, 02 12117 1632 332 332 332 16,293 60,518 NA 1681 1683 16,449 61,204 16,559 61,704 16,751 62,348 16,976 62,950
  • 21. 9.0 (March, 2006) 17,320 63,817 1682 17505 64,620 332 1682 17719 17,867 65,147 332 1,688  18,075 66,135 18,209 66,587  18483 67159 18641 67503 18,786  68,258  18,919  68,661  1,710  19,086  69,019  1710 1,713 19294 19,550 69524 70,177 1713 19737 70634 20057 71236 332 9.1 (January, 2007) 10.0 ( April, 2007) 10.1(September 1, 2007 ) 11.0 (March, 2008) 11.1 (1 September , 2008) 12.0 (March, 2009) 12.1 (September 2009) 13.0 (March 2010 ) 13.1 (September 2010) 14.0 (March 2011)  333 1699 335 1709 335 14.1 (1 September 2011  15.0 ( March, 2012) 15.1 ( September, 2012) 16 ( March, 2013) 65,605 335
  • 23.  Use of different types of terminologies Most organizations processing regulatory data used one of the international adverse drug reaction terminologies in combination with morbidity terminology. Europe United States European Union WHO-ART ICD-9 Japan J-ART J-MEDIS COSTART(C) ICD-9-CM Individualized Modified Terminologies to Suit Individual need. Major Technical Lacunae:  Lacked specificity of terms at the data entry level,  Provided limited data retrieval options (e.g., too few levels in the hierarchy, or capacity to retrieve data via one axis only), and  Ineffective handling of syndromes. Solution: Organizations with sufficient resources developed their terminologies to address some or all of these deficiencies. own “in-house”
  • 24. The use of multiple terminologies raised several problems:  Use of different terminologies for various cycle: Phases of regulatory Complicates data retrieval and analysis, making it difficult to cross-reference data. For example, for Pre-registration clinical trials safety data had frequently been classified by using ICD terminology and for post-marketing surveillance using JART, WHO-ART, or COSTART.  Protracted International Communication: Using different terminologies in separate geographic regions impaired international communication and necessitated the conversion of data from one terminology to another. This data conversion had the potential to cause time delays and loss or distortion of data.  The use of multiple terminologies also affected communication between companies and clinical research organizations. It became increasingly difficult to manage the information required for product registration applications and to meet the time scale requirements for data exchange between regulatory authorities and the medical product industries.
  • 26. The MedDRA Terminology applies to all phases of drug development (including biologicals but excluding animal toxicology). It also applies to the health effects and malfunction of devices (e.g., Catheter related infection and device leakage). The categories of “medical” terms are as follows:  symptoms Although social circumstances are not usually regarded as medical terms, they fall within signs the “medical” scope if they are relevant to the evaluation  of regulatory data diseases (e.g., in the assessment of clinical outcome of treatment in the light  diagnoses of exposure to  risk factors). therapeutic indications  names and qualitative results of investigations, Examples are: including pharmacokinetics the preferred term Foreign travel, the preferred term Occupational  surgical and the high level terms exposure to toxic agent and medical procedures Tobacco use and Bereavement.  medical/social/family history
  • 27. The above defined terminology, was developed for regulators and the regulated medical product industry. data entry, retrieval, evaluation and presentation, and in both pre- and postmarketing phases of the regulatory process as follows: Hence, these groups can utilize the terminology for clinical studies reports of spontaneous adverse reactions and events  regulatory submissions regulated product information
  • 28. Inclusion of terms from established terminologies The MedDRA Terminology includes references to other terminologies J-ART (1996) Preferred Terms, Included Terms COSTART (Fifth Edition  Preferred Terms, Glossary Terms WHO-ART© (3rd Quarter, 1998)  Preferred Terms, Included Terms  ICD-9 ICD-9-CM (4th revision) Not Specified HARTS (Release 2.2) The terminology was not developed as a metathesaurus and the hierarchies of these other terminologies are not subsets of it. Thus, data entry terms from other terminologies do not necessarily have the same PT (Preferred Term) in the MedDRA terminology as they did in their “parent” terminology. The hierarchies used for data retrieval and presentation are unique to the MedDRA.
  • 29. Exclusion Criteria The exclusion criteria used in the development of the terminology do not necessarily limit the terminology’s expansion scope. 1. Since this is a medical terminology, the following terms used in regulatory affairs are out of scope:  Drug/product terminology  Equipment/device/diagnostic product terminology  Study design  Demographics (including patient sex, age, race and religion) 2. As its focus is on health effects in individual patients, the following are excluded:  Failure of devices (except for a small number of clinically relevant terms) Qualifiers that refer to populations rather than individual patients, e.g., rare, frequent 
  • 30. Exclusion Criteria 3. Inclusion of terms is restricted to those within the scope of the terminology as defined above. Thus, when terms from a particular field (e.g., clinical pharmacology) are represented, only terms relevant to regulatory affairs should be included. 4. Numerical values associated with parameters are not included. 5. As a rule, descriptors of severity are not included in the terminology. Terms such as severe and mild are used only when pertinent to the specificity of the term (e.g., severe versus mild retardation).
  • 31. OUT IN Diseases Diagnoses Signs Drug product terms failure terms Device Symptoms Therapeutic indications Investigation Equipment, device, names & Numericalqualitative results values for diagnostic product terms results Medical & surgical procedures Medical, social, family history Medication Error Terms study Severity descriptorsfrom: design Clinical trial COSTARTterms Population-level terms Patient demographicqualifiers WHO-ART© HARTS J-ART
  • 32. MedDRA Term vs. MedDRA Code MedDRA Term: a word(s) Urticaria MedDRA Code: numbers representing each term Urticaria 10046735
  • 33. MedDRA Code Unique numerical number assigned to each term in the dictionary : 8 digits •Starts with alphabetically 10000001, initially started •As terms added, codes assigned sequentially •These are just identification numbers; they don’t reflect the relational organization of the data files (unlike WHO-ART)
  • 34. Development Philosophy • Based upon ANSI Z911 standard (American National Standards Institute standard for the development of a thesaurus) • Provided structure for development and future maintenance activities • Chosen to ensure the product would support the use of information technology • Internationally recognized standard 34
  • 35. Basic of Structural Elements of the Terminology
  • 36. Structural Elements of the Terminology Relationships between terms in the terminology fall into the following three categories: 1. Equivalence The equivalence relationship groups synonymous terms, or equivalent terms, under Preferred Terms. 2. Hierarchical The hierarchy provides degrees or levels of superordination and subordination. The superordinate term is a broad grouping term applicable to each subordinate descriptor linked to it. 3.Associative Associative groupings of terms are linked horizontally in the terminology.
  • 37. Hierarchy Hierarchies are an important mechanism for flexible data retrieval and for the clear presentation of data. The five level hierarchy in this terminology provides options for retrieving data by specific or broad groupings, according to the level of specificity required. The Lowest Level Term (LLT) level provides maximum specificity.
  • 38. Hierarchy System Organ Class (SOC) Link High Level Group Term (HLGT) Vertical High Level Term (HLT) Preferred Term (PT) Lowest Level Term (LLT) SSC or SMQ Detail discussion will be on later phases of discussion
  • 39. Example: SOC Blood and lymphatic system disorders HLGT White Blood Cell Disorder HLT Neutropenias PT Neutropenia LLT Neutropenia aggravated LLT Neutropenia SSC Bone Marrow Depression and Secondary immunocompromised State
  • 40. Example: SOC Cardiac Disorders HLGT Cardiac Arrhythmias HLT Rate and Rhythm of Disorders NEC PT Arrhythmia LLT Arrhythmia NOS LLT Arrhythmia LLT (Non-current) Other Specified Cardiac Dysrhythmias LLT Dysrhythmias
  • 41. System Organ Class (SOC) Highest level of the hierarchy that broadest concepts for data retrieval. provides the SOCs identified or grouped by Anatomical or physiological system or manifestation site (Gastrointestinal disorder) Etiology (Infection of Infestation) Purpose (Surgical and Medical procedure)
  • 42. Anatomical or physiological system or manifestation site or Anatomy (Body System) 1.Blood and lymphatic system disorders 9. Musculoskeletal and connective tissue disorders 10. Nervous system disorders 2.Cardiac disorders 11. Psychiatric disorders 3.Ear and labyrinth disorders 12. Renal and urinary disorders 4.Endocrine disorders 5.Eye disorders 6.Gastrointestinal disorders 7.Hepatobiliary disorders 8.Immune system disorders 13. Reproductive system and breast disorders 14. Respiratory, thoracic and mediastinal disorders 15. Skin and subcutaneous tissue disorders 16. Vascular disorders
  • 43. Other (Cause/Association) System Organ Class (SOC) 1.Congenital, familial and genetic disorders 2.General disorders and administration site conditions 3.Infections and infestations 4.Injury, poisoning and procedural 6. Metabolism and nutrition disorders 7. Neoplasms benign, malignant and unspecified (including cysts and polyps) 8. Pregnancy, puerperium and perinatal conditions complications 5.Investigations 9. Social circumstances 10. Surgical and medical procedures
  • 44. Etiology-based SOCs Supporting SOCs 1.Congenital, familial and genetic 1.Investigations disorders 2.Social circumstances 2.Neoplasms benign, malignant and 3.Surgical and medical procedures unspecified (including cysts and polyps) 3.Infections and infestations
  • 45. High Level Group Term ( HLGT ) Subordinate only to System Organ Classes and superordinate descriptor for one or more HLTs related to anatomy, pathology, physiology, etiology or function. SOC Gastrointestinal disorders HLGT Dental and gingival conditions HLGT Gastrointestinal infections HLGT Gastrointestinal vascular conditions
  • 46. High Level Term (HLT) Subordinate to HLGTs and super descriptors for the PTs linked to it. ordinate Categories linked to PTs by anatomy, pathology, physiology, etiology or function. Used solely presentation for data retrieval ( not a coding level). and
  • 47. High Level Term SOC Gastrointestinal disorders   HLGT Gastrointestinal infections   HLT Intestinal infections HLT Gastrointestinal infections, site unspecified HLT Peritoneal infections
  • 48. HLGT Vascular Hypertensive Disorder   HLT Accelerated and malignant Hypertension HLT Pregnancy Associated with hypertension HLT Hypertension complication HLT Portal hypertension HLT Pulmonary hypertension
  • 49. Preferred Term   Each Preferred Term represents a single medical concept: • Clinical pathologic /etiologic data represented at PT level. • Unambiguous, self- descriptive. • No limit to the amount of LLTs that can be associated with a single PT ( A PT must have at least one LLT linked to it). • When a new PT is added an identical LLT is created automatically for data entry purposes.
  • 50. • A PT must be linked to at least one SOC. Each path to a SOC from a PT should have exactly one HLT and HLGT (one route) PT → HLT → HLGT → SOC • PTs can be represented in multiple SOCs (multiaxality) • PTs may be groups with other PTs from the same SOC or different SOCs in SSC for cross hierarchy searches.
  • 51. Example of PT PT Headache LLT (Non-current) LLT Head Pain LLT Head Pressure LLT Head aggravated Head dull LLT Head fullness LLT Headache LLT Head throbbing
  • 52. Example of PT PT Dysponea LLT (Non-current) LLT Air Hunger LLT Breath Shortness Breathlessness LLT Breathing Difficult LLT Dysponea LLT Difficult breathing
  • 53. Lowest Level Term (LLT) The most Specific level of terminology. Facilitate the data transfer from other terminologies. Facilitate the data entry by subjective choice. Use for Auto coding.
  • 54. Lowest Level Term (LLT) Important Features: Each LLT is linked to only one preferred descriptor in the terminology. PT; this is its Has one of the following relationships to the Preferred Term (PT)  Synonyms  Lexical variants  Quasi-synonym  Sub-element  Identical LLT
  • 55. Synonyms Different terms for the for the same descriptor same concept inherent in the PT For Example: PT Arthritis LLT Joint Inflammation
  • 56. Lexical variants Different word forms for the same expression These include full names vs. abbreviations For Example: PT Acquired immunodeficiency syndrome LLT AIDS OR direct vs. inverted word order PT Biopsy tongue LLT Tongue biopsy
  • 57. Quasi-synonym Terms that are not precisely the same meaning as another term, but are treated as synonymous in a given terminology. PT Otitis externa LLT Bilateral otitis externa Based on site and laterality descriptions both the terms are considered as Synonymous or equivalent clinically for medical product regulatory purposes.
  • 58. Sub-element Sub-elements (of the parent PT) are represented by LLTs with more detailed information such as anatomic specificity. PT Contusion LLT Bruising of face LLT Bruising of leg
  • 59. Identical LLT One LLT is identical to its PT for data entry purposes PT Arrhythmia LLT Arrhythmia NOS LLT Arrhythmia LLT (Non-current) Other Specified Cardiac Dysrhythmias LLT Dysrhythmias PT Dementia Alzheimer’s type LLT Dementia Alzheimer’s type In these instance, the LLT and parent PT have the same MedDRA code but appear at both levels.
  • 60. Basic Rules in MedDRA PT: British Spelling LLT: British and American Spelling Medical Term: Dorland’s Medical Dictionary (29th Ed) Non-Medical Term: Merrian-Webster English Dictionary (29th Ed)
  • 62. But First, Some Definitions • Controlled vocabulary: a bunch of words, no relationships – But there is advantage if all users use the same terms to describe things • Taxonomy: is a controlled vocabulary with hierarchy • Thesaurus: is interchangeable with controlled vocabulary, also sometimes referred to as an ontology • Ontology: all of the above; think neural network with a bunch of relationships • MetaData: data about data (I really hate this definition, but it’s accurate) • MetaThesaurus – a collection of all of these things – EXAMPLE: UMLS
  • 63. UMLS – Unified Medical Language System • More than 5 million terms or named entities • Divided into concepts, and each term has unique identifier • Not a vocabulary, but a mapping BETWEEN vocabularies • Vocabularies included in the UMLS: – – – – MeSH Headings in 8 languages (MeSH = Medical Subject Headings) ICPC-93 in 14 languages (ICPC = International Classification of Primary Care) WHO Adverse Drug Reaction Terminology in 5 languages SNOMED-2, SNOMED-3, and UK Clinical Terms (former Read Codes) (SNOMED = Systemized Nomenclature of Medicine) – ICD-10 in English and German (ICD = International Classification of Diseases)

Notas del editor

  1. ICH ADDRESSED SEVERAL EFFICACY TOPICS (Status as of July 97) E1 The extent of population exposure to assess clinical safety : Adopted Oct 94 E2A Clinical safety data management : Definitions and standards for expedited reporting : Adopted Oct 94 E2B Clinical safety data management : Data elements for transmission of ADR reports : Step 4, Jul 97 E2C Clinical safety data management : Periodic safety updates : Step 4 Nov 96 E3 Clinical study reports: Structure and content : Adopted Nov 95 E4 Dose response information to support drug registration : Adopted Mar 94 E5 Ethnic factors in acceptability of foreign clinical data : Step 2 Draft Mar 97 E6 Good clinical practice: consolidated guideline :Adopted May 96 E7 Clinical trials in special populations : Geriatrics: Adopted Jun 93 E8 General considerations for clinical trials : Step 4 Jul 97 E9 Statistical considerations in the design of clinical trials : Step 2 Draft Jan 97 E10 Choice of control group in clinical trials : will be developed EFTA - European Free Trade Association
  2. (